Frequency and Radiation Pattern Reconfigurable Multiband Microstrip Monopole Antenna

Issa, Saeed H.; Al-Makdadi, Qusai W.; Al-Juwhari, Mohammad H.; Sabbah, Zaid A.; Faouri, Yanal S.

doi:10.1109/gc-eleceng52322.2021.9788136

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The AUGMENT-101 trial (NCT04065399) is a first-in-human phase (Ph) 1 study to determine the safety, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and pharmacokinetic (PK) profile of remuvenib in patients with relapsed or refractory (R/R) acute leukemia [22][23][24][25]. Patients enrolled in this trial are heavily pretreated and have a very poor prognosis.…”

Section: A Revumenibmentioning

confidence: 99%

“…Interestingly, ziftomenib is metabolized to at least two metabolites with comparable activity to ziftomenib itself. The KOMET-001 trial (NCT04067366) is an ongoing open-label phase1/2A study evaluating ziftomenib monotherapy in adult patients with R/R acute leukemia [23]. No dose-limiting toxicities (DLTs) occurred during the dose escalation phase of the study within the 28-day DLT assessment window.…”

Section: B Ziftomenibmentioning

confidence: 99%

See 1 more Smart Citation

Menin Inhibitors: New Players in KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia

Coppola,

Candoni

2024

Preprint

View full text Add to dashboard Cite

Menin inhibitors are new and promising agents currently in clinical development that target the HOXA/MEIS1 transcriptional program which is critical for leukemogenesis in histone-lysine N-methyltransferase 2A rearranged (KMT2Ar) and in NPM1-mutated (NPM1mut) acute leukemia. The mechanism of action of this new class of agents is based on the disruption of menin-KMT2A complex (constitute of chromatin remodelling proteins), leading to the differentiation and apoptosis of AML cells expressing KMT2A or mutated NPM1. This new class of drugs has been tested alone, or in combination with synergistic drugs, in phase I and II clinical trials (AUGMENT-01 and 02, KOMET-01 and 07, SAVE, COVALENT trial and others), showing promising results in terms of response rates and safety in heavily pre-treated acute leukemia patients. In this review, we summarise the key findings on menin inhibitors, focusing on the mechanism of action and preliminary clinical data of this emerging and promising class of agents, in particular revumenib and ziftomenib.

show abstract

Section: A Revumenibmentioning

confidence: 99%

Section: B Ziftomenibmentioning

confidence: 99%